Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulopenem versus ertapenem step-down therapy for complicated urinary tract infection
2017-003772-31Phase 3Completed
- Sponsor
- Iterum Therapeutics plc
- Start
- Aug 2018
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sulopenem, ertapenem, ciprofloxacin, amoxicillin + clavulanate and probenecid in complicated urinary tract infection (cUTI) (2 arms), sponsored by Iterum Therapeutics plc. Primary endpoint: Overall response at test of cure. Started Aug 2018; status: completed.
02
Drugs
sulopenemertapenemciprofloxacinamoxicillin + clavulanateprobenecid
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on 2017-003772-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003772-31.